Literature DB >> 36269395

Cost effectiveness of melanoma in situ resection and repair by dermatology compared to non-dermatology specialties at a single institution.

Kevin M Burningham1, Kim Le1, Annie He1, Madeleine O'Brian1, Kevin Shi2, Divya Srivastava2, Rajiv I Nijhawan3.   

Abstract

Melanoma-in-situ (MIS) is treated with surgical resection by many specialties. Dermatologists perform these procedures in outpatient settings while others often employ operating rooms and general anesthesia. We hypothesized that MIS managed by dermatology was less costly than that managed by other specialties. All cases of MIS treated at our institution over a 3-year period were evaluated retrospectively for demographic and clinical characteristics and categorized by treating specialty. Estimated cost information was determined using records of charges billed. The mean total cost for MIS treated with wide local excision (WLE) by dermatologists was $1089 (CI = $941-1237) versus all other specialties at $5172 (CI = $2419-7925) (p < 0.001). MIS treated with Mohs micrographic surgery and repaired by dermatology (mean = $2325, CI = $2241-2409) was also less expensive than MIS treated by other specialties with WLE (p < 0.001). The results suggest MIS is significantly less costly to patients and the health care system when treatment is performed by dermatologists compared to other surgical specialties. This is likely due to dermatologists performing the procedures in less expensive outpatient settings.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Costs and cost analysis; Melanoma in situ; Mohs micrographic surgery; Wide local excision

Year:  2022        PMID: 36269395     DOI: 10.1007/s00403-022-02405-4

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.033


  5 in total

1.  Guidelines of care for the management of primary cutaneous melanoma.

Authors:  Susan M Swetter; Hensin Tsao; Christopher K Bichakjian; Clara Curiel-Lewandrowski; David E Elder; Jeffrey E Gershenwald; Valerie Guild; Jane M Grant-Kels; Allan C Halpern; Timothy M Johnson; Arthur J Sober; John A Thompson; Oliver J Wisco; Samantha Wyatt; Shasa Hu; Toyin Lamina
Journal:  J Am Acad Dermatol       Date:  2018-11-01       Impact factor: 11.527

2.  AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.

Authors:  Suzanne M Connolly; Diane R Baker; Brett M Coldiron; Michael J Fazio; Paul A Storrs; Allison T Vidimos; Mark J Zalla; Jerry D Brewer; Wendy Smith Begolka; Timothy G Berger; Michael Bigby; Jean L Bolognia; David G Brodland; Scott Collins; Terrence A Cronin; Mark V Dahl; Jane M Grant-Kels; C William Hanke; George J Hruza; William D James; Clifford Warren Lober; Elizabeth I McBurney; Scott A Norton; Randall K Roenigk; Ronald G Wheeland; Oliver J Wisco
Journal:  J Am Acad Dermatol       Date:  2012-09-05       Impact factor: 11.527

3.  A Retrospective Case-Matched Cost Comparison of Surgical Treatment of Melanoma and Nonmelanoma Skin Cancer in the Outpatient Versus Operating Room Setting.

Authors:  Ryan P Johnson; Niraj Butala; Murad Alam; Naomi Lawrence
Journal:  Dermatol Surg       Date:  2017-07       Impact factor: 3.398

4.  Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.

Authors:  Adi Nosrati; Jacqueline G Berliner; Shilpa Goel; Joseph McGuire; Vera Morhenn; Juliana R de Souza; Yildiray Yeniay; Rasnik Singh; Kristina Lee; Mio Nakamura; Rachel R Wu; Ann Griffin; Barbara Grimes; Eleni Linos; Mary Margaret Chren; Roy Grekin; Maria L Wei
Journal:  JAMA Dermatol       Date:  2017-05-01       Impact factor: 10.282

5.  Total Margin-Controlled Excision is Superior to Standard Excision for Keratinocyte Carcinoma on the Nose: A Veterans Affairs Nested Cohort Study.

Authors:  Paul R Massey; Sameer Gupta; Brooke E Rothstein; Nellie Konnikov; Meera Mahalingam; Emily S Ruiz; Chrysalyne D Schmults; Abigail Waldman
Journal:  Ann Surg Oncol       Date:  2021-03-19       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.